Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 35 (December 10), 2006: pp. 5576-5583
Published by the American Society of Clinical Oncology
DOI: 10.1200/JCO.2006.08.3774

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, J. C.
Right arrow Articles by Childs, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J. C.
Right arrow Articles by Childs, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Immunotherapy for Renal Cell Cancer

James C. Yang, Richard Childs

From the Surgery Branch, Center for Cancer Research, National Cancer Institute; and the National Heart Lung and Blood Institute, Bethesda, MD

Address reprint requests to James C. Yang, National Cancer Institute, Room CCR/3-5952, 9000 Rockville Pike, Bethesda, MD 20892; e-mail: jamesyang{at}mail.nih.gov

For eligible patients, the value of immunotherapy for metastatic clear-cell renal cancer is its curative potential, as demonstrated by long-term follow-up after interleukin-2. Advances in cellular therapies, manipulation of activating and inhibitory receptors on T cells and modification of allotransplantation regimens have all produced new tumor regressions in patients who did not respond to conventional interleukin-2 regimens. It is clear that renal cancer remains one of the most immunoresponsive of human malignancies and that advances in immune modulation are again translating into clinical responses for patients with this disease. As the array of biologic therapies for renal cancer expands with the approval of tyrosine kinase inhibitors, immunotherapy, the only modality that can cure widespread renal cancer, must not be overlooked.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Krusch, J. Salih, M. Schlicke, T. Baessler, K. M. Kampa, F. Mayer, and H. R. Salih
The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro
J. Immunol., December 15, 2009; 183(12): 8286 - 8294.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
K. Ishiyama, A. Takami, S. Suzuki, H. Konaka, M. Namiki, A. Ooi, and S. Nakao
Relationship Between Tumor-infiltrating T Lymphocytes and Clinical Response After Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Renal Cell Carcinoma: A Single Center Prospective Study
Jpn. J. Clin. Oncol., December 1, 2009; 39(12): 807 - 812.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
R. Lichtenfels, S. P. Dressler, M. Zobawa, C. V. Recktenwald, A. Ackermann, D. Atkins, M. Kersten, A. Hesse, M. Puttkammer, F. Lottspeich, et al.
Systematic Comparative Protein Expression Profiling of Clear Cell Renal Cell Carcinoma: A PILOT STUDY BASED ON THE SEPARATION OF TISSUE SPECIMENS BY TWO-DIMENSIONAL GEL ELECTROPHORESIS
Mol. Cell. Proteomics, December 1, 2009; 8(12): 2827 - 2842.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Shablak, R. E. Hawkins, D. G. Rothwell, and E. Elkord
T Cell-Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective
Clin. Cancer Res., November 1, 2009; 15(21): 6503 - 6510.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Shanker, A. D. Brooks, K. M. Jacobsen, J. W. Wine, R. H. Wiltrout, H. Yagita, and T. J. Sayers
Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity
Cancer Res., August 15, 2009; 69(16): 6615 - 6623.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Norell, T. Martins da Palma, A. Lesher, N. Kaur, M. Mehrotra, O. S. Naga, N. Spivey, S. Olafimihan, N. G. Chakraborty, C. Voelkel-Johnson, et al.
Inhibition of Superoxide Generation upon T-Cell Receptor Engagement Rescues Mart-127-35-Reactive T Cells from Activation-Induced Cell Death
Cancer Res., August 1, 2009; 69(15): 6282 - 6289.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Ko, A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. Rayman, L. Wood, J. Garcia, et al.
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Clin. Cancer Res., March 15, 2009; 15(6): 2148 - 2157.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. S. Tykodi, N. Fujii, N. Vigneron, S. M. Lu, J. K. Mito, M. X. Miranda, J. Chou, L. N. Voong, J. A. Thompson, B. M. Sandmaier, et al.
C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients
Clin. Cancer Res., August 15, 2008; 14(16): 5260 - 5269.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. S. Hinrichs, R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer, C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, and N. P. Restifo
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Blood, June 1, 2008; 111(11): 5326 - 5333.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Wittnebel, S. Da Rocha, J. Giron-Michel, A. Jalil, P. Opolon, B. Escudier, P. Validire, K. Khawam, S. Chouaib, B. Azzarone, et al.
Membrane-Bound Interleukin (IL)-15 on Renal Tumor Cells Rescues Natural Killer Cells from IL-2 Starvation-Induced Apoptosis
Cancer Res., June 15, 2007; 67(12): 5594 - 5599.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. F. Bajorin, R. J. Motzer, and G. J. Bosl
Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research
J. Clin. Oncol., December 10, 2006; 24(35): 5479 - 5481.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online